|
|
|
|
-
Array BioPharma Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
5/6/2013
|
-
Array BioPharma Posts Q3 Loss Per Share Of $0.19 Vs. Loss $0.11 Year Ago
5/6/2013
|
-
Array BioPharma Appoints Michael Needle As Chief Medical Officer
3/21/2013
|
|
|
-
Array Biopharma, Global Blood Therapeutics Announce Drug Discovery Collaboration Focused On Hematology
3/5/2013
|
|
|
|
|
|
|